19 patents
Utility
Treatment of Cancer Using Inhibitors of Tgf-beta and PD-1
28 Dec 23
The present disclosure relates, in general, to combination therapy using an inhibitor of transforming growth factor beta (TGFβ) and an inhibitor of programmed cell death protein 1 (PD-1) for treating cancer or preventing recurrence of cancer diseases such as lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma, and metastases thereof.
Amer M Mirza, Rosemary J. Akhurst, Ou Li
Filed: 11 May 23
Utility
Compositions and Methods for Delaying the Incidence of Labor
23 Nov 23
The invention provides compositions and methods for delaying the onset of delivery in a pregnant subject, such as a pregnant human subject, that is undergoing or at risk of undergoing preterm labor at a gestational age of from about 24 weeks to about 34 weeks.
Jean-Pierre GOTTELAND, Oliver POHL
Filed: 16 Dec 22
Utility
Parathyroid hormone receptor 1 (PTH1R) antibodies and uses thereof
17 Oct 23
The present disclosure relates, in general, human antibodies against human parathyroid hormone receptor 1 (PTH1R) and methods of use of such antibodies in the treatment of cancer, Humoral Hypercalcemia of Malignancy (HHM), or Primary Hyperparathyroidism (PHPT) and Secondary Hyperparathyroidism (SHPT) and cachexia.
Raphael D. Levy, Hassan Issafras, Agnes Choppin Holmes, Kirk W. Johnson, Amer M. Mirza, Daniel H. Bedinger, Rachel A. Hunt, Toshihiko Takeuchi, Kiranjit Kaur Ahluwalia, Robyn Cotter
Filed: 26 Nov 19
Utility
Method of increasing the ratio of effector T cells to regulatory T cells in a tumor by administering to a subject a TGF-beta inhibitor and a PD-1 antibody
27 Jun 23
The present disclosure relates, in general, to combination therapy using an inhibitor of transforming growth factor beta (TGFβ) and an inhibitor of programmed cell death protein 1 (PD-1) for treating cancer or preventing recurrence of cancer diseases such as lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma, and metastases thereof.
Amer M. Mirza, Rosemary J. Akhurst, Ou Li
Filed: 15 Jun 20
Utility
Compositions and methods for delaying the incidence of labor
27 Dec 22
The invention provides compositions and methods for delaying the onset of delivery in a pregnant subject, such as a pregnant human subject, that is undergoing or at risk of undergoing preterm labor at a gestational age of from about 24 weeks to about 34 weeks.
Jean-Pierre Gotteland, Oliver Pohl
Filed: 14 May 19
Utility
Novel Modulators
21 Jul 22
Antibodies that modulate insulin receptor signaling are provided.
John Corbin, Mark Leslie White, Susan R. Watson, Vinay Bhaskar
Filed: 13 Jan 22
Utility
Modulators
1 Mar 22
Antibodies that modulate insulin receptor signaling are provided.
John Corbin, Mark Leslie White, Susan R. Watson, Vinay Bhaskar
Filed: 14 Mar 18
Utility
Antibodies Specific for TGF-Beta
18 Nov 21
The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGFβ), including TGFβ1, TGFβ2 and TGFβ3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGFβ expression.
Daniel H. Bedinger, Shireen S. Khan, Amer M. Mirza, Ajay J. Narasimha, Toshihiko Takeuchi
Filed: 15 Jul 21
Utility
Method of treating cancer by administering an antibody that binds transforming growth factor beta (TGF-beta) 1, TGF-beta 2 and TGF-beta 3
24 Aug 21
The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGFβ), including TGFβ1, TGFβ2 and TGFβ3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGFβ expression.
Daniel Bedinger, Shireen S. Khan, Amer Mirza, Ajay J. Narasimha, Toshihiko Takeuchi
Filed: 7 Jun 19
Utility
Antibodies That Bind INTERLEUKIN-2 and Uses Thereof
24 Jun 21
The present disclosure relates, in general, to human antibodies against human interleukin 2 (IL-2) and methods of use of such antibodies for modulating IL-2 activity and use in the treatment of conditions such as cancer, autoimmune disease, or infection.
Marina Roell, Mark Rubinstein, Hassan Issafras, Llewelyn Lao, Ou Li, Daniel H. Bedinger, Kristin Camfield Lind, Agnes Choppin Holmes, Toshihiko Takeuchi, Lauren Schwimmer, Hoa Giang, Amer M. Mirza, Kirk W. Johnson
Filed: 4 Dec 20
Utility
Humanized M-CSF specific monoclonal antibodies, kits, and uses thereof
15 Jun 21
M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William Michael Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
Filed: 12 Oct 18
Utility
Methods for the Treatment of Gout
4 Feb 21
Disclosed are methods for the treatment and/or prevention of gout, comprising administering to a subject an effective amount of anti-IL-1β antibody or fragment thereof.
Alan M. Solinger
Filed: 13 Mar 20
Utility
Cardiovascular Related Uses of IL-1BETA Antibodies and Binding Fragments Thereof
14 Jan 21
Disclosed are methods for the reduction, prevention or treatment of cardiovascular events and/or cardiovascular diseases, including acute cardiovascular disease or chronic cardiovascular disease using anti-IL-1β binding molecules (e.g., IL-1β binding antibodies and fragments thereof).
Patrick J. Scannon, Alan M. Solinger, Jeffrey D. Feldstein
Filed: 24 Feb 20
Utility
Antibodies that bind interleukin-2 and uses thereof
7 Dec 20
The present disclosure relates, in general, to human antibodies against human interleukin 2 (IL-2) and methods of use of such antibodies for modulating IL-2 activity and use in the treatment of conditions such as cancer, autoimmune disease, or infection.
Marina Roell, Mark Rubinstein, Hassan Issafras, Llewelyn Lao, Ou Li, Daniel H. Bedinger, Kristin Camfield Lind, Agnes Choppin Holmes, Toshihiko Takeuchi, Lauren Schwimmer, Hoa Giang, Amer M. Mirza, Kirk W. Johnson
Filed: 27 Sep 17
Utility
Parathyroid Hormone Receptor 1 (PTH1R) Antibodies and Uses Thereof
7 Oct 20
The present disclosure relates, in general, human antibodies against human parathyroid hormone receptor 1 (PTH1R) and methods of use of such antibodies in the treatment of cancer, Humoral Hypercalcemia of Malignancy (HHM), or Primary Hyperparathyroidism (PHPT) and Secondary Hyperparathyroidism (SHPT) and cachexia.
Raphael D. Levy, Hassan Issafras, Agnes Choppin Holmes, Kirk W. Johnson, Amer M. Mirza, Daniel H. Bedinger, Rachel A. Hunt, Toshikiko Takeuchi, Kiranjit Kaur Ahluwalia, Robyn Cotter
Filed: 25 Nov 19
Utility
Treatment of Cancer Using Inhibitors of TGF-Beta and PD-1
30 Sep 20
The present disclosure relates, in general, to combination therapy using an inhibitor of transforming growth factor beta (TGFβ) and an inhibitor of programmed cell death protein 1 (PD-1) for treating cancer or preventing recurrence of cancer diseases such as lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma, and metastases thereof.
Amer M. Mirza, Rosemary J. Akhurst, Ou Li
Filed: 14 Jun 20
Utility
Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
13 Jul 20
The present disclosure relates, in general, to methods of treating or preventing post-prandial hypoglycemia after gastric bypass surgery using a negative modulator antibody that binds to the insulin receptor and modulates the action of insulin at the insulin receptor.
Kirk W. Johnson, Rajneesh Nath, Paul Rubin
Filed: 2 Mar 16
Utility
Treatment of cancer using anti-TGF-β and anti-PD-1 antibodies
15 Jun 20
The present disclosure relates, in general, to combination therapy using an inhibitor of transforming growth factor beta (TGFβ) and an inhibitor of programmed cell death protein 1 (PD-1) for treating cancer or preventing recurrence of cancer diseases such as lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma, and metastases thereof.
Amer M. Mirza, Rosemary J. Akhurst, Ou Li
Filed: 16 Dec 18
Utility
Cardiovascular related uses of IL-1β antibodies and binding fragments thereof
6 Apr 20
Disclosed are methods for the reduction, prevention or treatment of cardiovascular events and/or cardiovascular diseases, including acute cardiovascular disease or chronic cardiovascular disease using anti-IL-1β binding molecules (e.g., IL-1β binding antibodies and fragments thereof).
Patrick J. Scannon, Alan M. Solinger, Jeffrey D. Feldstein
Filed: 10 Jul 17
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first